Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib-Reference-Cited by-同舟云学术

Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib

Published:2024-01-27 Issue:7 Volume:130 Page:1141-1148
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Gaillard Thomas^ORCID,Piketty Jeanne,Feron Jean-Guillaume,Girard Noemie,Pauly Lea,Gauroy Elodie,Darrigues Lauren,Grandal Beatriz,Pierga Jean-Yves^ORCID,Hamy-Petit Anne-Sophie,Reyal Fabien^ORCID,Laas Enora

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02580-3.pdf

Reference30 articles.

1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.

2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol J Eur Soc Med Oncol. 2011;22:1736–47.

3. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015). Breast Edinb Scotl. 2018;39:131–8.

4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.

5. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116–24.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?;Cancers;2024-09-04

2. Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial;The Lancet Oncology;2024-09

3. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study;eClinicalMedicine;2024-05

4. Axillary Surgery for Breast Cancer in 2024;Cancers;2024-04-23